Loading patent…
AssigneeJiangsu Nuo-Beta Pharmaceutical Technology Co. Ltd.
InventorsFude Huang, Xiao Zhang, Wenan Wang, Le Zhang, Lixiang Jiang, Tong Zhu, Haiyan Liu, Yudong Zhou, Yang He, Wanguo Wei
Estimating the term…
The use of a genetic method to down-regulate RBO/EFR3/EFR3A/EFR3B proteins, TTC7 protein or PI4KIIIα enzyme protein which interacts with RBO/EFR3/EFR3A/EFR3B proteins and TTC7 protein, or the use of a drug to inhibit PI4KIIIα protein kinase activity reduces the accumulation of Aβ42 within neurons and age-dependent synaptic transmission failure and other obstacles in a fruit fly AD model, and obtains an effect of improving the learning and memory abilities of AD model mice. Provided is a method for using an RBO/EFR3/EFR3A/EFR3B inhibitor, a TTC7 inhibitor and a PI4KIIIα inhibitor to treat Alzheimer's disease. Also provided is a method for screening a drug treating Alzheimer's disease by whether Aβ secretion by nerve cells is promoted or not.
A method for treating ameliorating or inhibiting Alzheimer's disease and its symptoms in a subject in need thereof, the method comprising administering to the subject a PI4KIIIα inhibitor.
Dependencies are inferred from the claim text.